ClinicalTrials.gg
Active, not recruitingNCT07749703Updated Aug 11, 2026

A Phase I Study of SIM0532 in Adult Participants With Advanced Solid Tumors

A Phase 1 interventional study of SIM0532 Tablets in Histologically or Cytologically Confirmed Advanced Solid Tumors, sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd.. Active, not recruiting at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd. (part of Simcere Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Mar 2026, registered Aug 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
346
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

an open-label, multicenter, Phase I study designed to evaluate the safety, tolerability, efficacy, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics of SIM0532 in participants with advanced solid tumors. The

study commences with a dose-escalation part (Part 1), followed by a dose-expansion part (Part 2).

Read the detailed description

Part 1 will be guided by the Bayesian Optimal Interval (BOIN) dose-escalation rule. In Part 2, patients with advanced pancreatic adenocarcinoma, RAS-mutant advanced non-small cell lung cancer (NSCLC) and other RAS-mutant advanced solid tumors.

02

Conditions studied

  • Histologically or Cytologically Confirmed Advanced Solid Tumors
03

In context

Lead sponsor

Jiangsu Simcere Pharmaceutical Co., Ltd. is the lead sponsor of 78 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Signed the form prior to performing the specified procedures required by the study.
  • 2. Aged ≥18 years.
  • 3. (ECOG) performance status score of 0 or 1.
  • 4. Expected survival ≥12 weeks.
  • 5. Laboratory test results indicating sufficient organ function.
  • 6. At least one per v1.1;

Exclusion criteria

Exclusion Criteria:

  • 1. A history of other malignant tumors within 2 years.
  • 2. With symptomatic central nervous system (CNS) .
  • 3. Gastrointestinal diseases that affect drug administration/absorption.
  • 4. Known psychiatric disorders or substance abuse that may interfere with the conduct of the study.
  • 5. Uncontrolled pleural effusion, pericardial effusion or ascites requiring drainage or medical intervention within 4 weeks.
  • 6. Any active infection requiring systemic treatment within 2 weeks.
  • 7. A history of non-infectious pneumonia requiring oral or intravenous therapy for recovery, or interstitial lung disease (ILD) or severe obstructive pulmonary disease.
  • 8. Previous treatment with RAS-targeting therapies other than RAS (OFF) inhibitors.
  • 9. Failure to recover from adverse events (AEs) caused by previous antineoplastic therapy.
  • 10. Currently participating in or having participated in a study of other drugs or devices within 4 weeks.
  • 11. Major surgery within 4 weeks.
  • 12. Previous antineoplastic therapy before the first dose of study treatment should have a certain
  • 13. Vaccination with any within 4 weeks.
  • 14. Known (HIV) infection or acquired immunodeficiency syndrome (AIDS).
  • 15. Active virus (HBV) or virus (HCV) infection;
  • 16. A history of cardiovascular disease.
  • 17. A history of allogeneic organ transplantation or (GVHD).
  • 18. Known to the study drug or any of its .
  • 19. Participants who are pregnant or breastfeeding.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
346 participants (estimated)

Study arms

  • Experimental
    Oral SIM0532

    Drug: SIM0532 Tablets

Interventions

  • DrugSIM0532 Tablets

    SIM0532 Tablets

06

What researchers measure

Primary outcomes

  1. Part 1: Dose-limiting toxicity (DLT)

    Time frame: Cycle 1 Day 1 (C1D1) to Cycle 1 Day 21 (C1D21) (Each cycle is 21 days)

  2. Part 1: Safety: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)

    Time frame: From informed consent signing to 30 days after the last dose

  3. Part 2: Incidence and severity of subjects with AEs/SAEs

    Time frame: From informed consent signing to 30 days after the last dose

  4. Part 2: Objective response rate (ORR)

    Time frame: About 24 months.

Secondary outcomes

  1. Maximum plasma concentration (Cmax)

    Time frame: About 24 months

  2. Duration of response (DOR)

    Time frame: About 24 months

  3. Disease control rate (DCR)

    Time frame: About 24 months

  4. Time to response (TTR)

    Time frame: About 24 months

  5. Overall survival (OS)

    Time frame: About 24 months

  6. Progression-free survival (PFS)

    Time frame: About 24 months

07

Study locations

6 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Jun 2028, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2026
First posted
Aug 6, 2026
StartActual
Mar 31, 2026
Primary completionEst.
Jun 30, 2028
CompletionEst.
Jun 30, 2030
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07749703
Collaborators
Shanghai Xianwei Medical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Aug 6, 2026
Start date
Mar 31, 2026
Primary completion
Jun 30, 2028 (estimated)
Completion
Jun 30, 2030 (estimated)
Last update
Aug 11, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion